Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study
Subcutaneous amivantamab administration substantially reduced IRRs, obviating the need for prolonged infusions and 2-day split-dosing at first administration. The identified RP2Ds for subcutaneous amivantamab are implemented in ongoing studies evaluating amivantamab regimens in NSCLC, colorectal cancer, and head and neck squamous cell carcinoma.
Authors
- Eileen Berkay
- Peter Hellemans
- Bert H. O’Neil (ORCID: https://orcid.org/0000-0001-7032-7453)
- Donna Zemlickis
- Busola Sanusi
- Roland E. Knoblauch
- Pamela L. Clemens (ORCID: https://orcid.org/0000-0001-5562-9824)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
- Anna Mitselos
- Lee Se-Hoon
- Joshua K. Sabari
- Mahadi Baig
- Ali Alhadab
- Anna Minchom
- Carmel Collins
- Byoung Chul Cho
- Ki Hyeong Lee
- Kamya Sankar
Institutions
- Cedars-Sinai Medical Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Johnson & Johnson (United States) (US)
- Institute of Cancer Research (GB)
- University of Toronto (CA)
- Yonsei University (KR)
- Providence Portland Medical Center (US)
- Samsung Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Bundang Hospital (KR)
- University of Manchester (GB)
- NYU Langone Health (US)
- Johnson & Johnson (Ireland) (IE)
- Sarah Cannon (US)
- Johnson Research & Development (United States) (US)
- The Christie NHS Foundation Trust (GB)
- Johnson & Johnson (Israel) (IL)
- Community Health Network (US)
- Johnson & Johnson (Brazil) (BR)
- Chungbuk National University Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.cllc.2026.02.001
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00